Obesity is linked to many accompanying comorbidities and has a substantial effect on the cost of health care. Pharmacist are able to provide management and intervention for the treatment of these disease states. This study examined outcomes 12 months prior to pharmacist intervention and 6 months postintervention. The primary outcome was to determine if pharmacist service intervention resulted in improved markers of weight and diabetes. This study revealed significant improvement in the HgbA1c and body mass index (BMI) from baseline (A1c 7.9%, BMI 35.3 kg/m 2 ) to postintervention (A1c 7%, BMI 34.1 kg/m 2 ). These results were statistically significant (P < .001, Bonferroni correction applied for multiple comparisons), indicating the clinical importance of adding pharmacists to the health care team in obesity and diabetes management.
Introduction
It is widely known that the United States is in the midst of an obesity epidemic. 1 The contributions of obesity to comorbid conditions, such as diabetes, hypertension, hyperlipidemia, cancer, and depression, are well established. Obesity also has a substantial effect on the cost of health care as the estimated annual medical cost related to complications and comorbidities of an obese person is approximately $1500 more than someone of normal weight. 2 In spite of current efforts to combat the epidemic both in the public health sector and in individual patient management, the problem continues to grow. In 2014, 36.5% of Americans were considered obese, and by 2015 at least 20% of the population in each state in the United States was considered obese. 3, 4 Healthy People 2020 guidelines have established goals to reduce obesity with the recommendation that all health care practitioners are involved. 5 Despite this, the role for pharmacists in obesity and weight loss management has not been well established. Research is needed to illustrate the success of pharmacy services in managing obesity.
A review of current literature available in MEDLINE showed there has been limited research published regarding pharmacist-managed weight management programs, with all showing some improvement in weight outcomes. [6] [7] [8] A review of these items is provided in Table 1 . Furthermore, a publication regarding satisfaction found that patients receiving obesity management services under the care of a pharmacist were satisfied and desired to continue consultations with the pharmacist. At present, there is no limited literature evaluating the efficacy of pharmacist-managed obesity compared to other standards of care, such as primary care. One weight management program in the United Kingdom showed no significant difference in the amount of weight loss between patients who attended programs managed by general practitioners and patients who attended programs managed by pharmacists. 6 In addition, there are a lack of strategies for pharmacists desiring to implement obesity management services.
The primary objective of this study was to establish whether a referral-based program offered by a pharmacist results in clinically significant weight loss compared to primary care alone. 
Methods

Design
This study is a retrospective case-control study in which patients served as their own control. The study was approved by a research review board at a Wingate University and approved by the health care system's research review committee. No informed consent was obtained based on the retrospective nature of the study.
Participants and Setting
The patient population was derived from all patients referred in 2015 to a disease-state management service led by 2 pharmacists (PharmD Clinic) in 2 separate clinic locations. The PharmD Clinic is a referral-based program in which primary care providers within a health system in North Carolina can refer patients to a clinical pharmacist, who is also a certified diabetes educator, for chronic disease state management. There were 2 clinics and 2 pharmacists who are certified diabetes educators utilized to receive referrals and complete the interventions. Interventions made included medication review and recommendations for changes. These changes include recommendations to initiate medications for treatment of obesity and diabetes per the appropriate guidelines for the disease state and to remove or adjust medications contributing to weight gain to the primary care provider. In addition, disease state and therapeutic lifestyle education is provided to the patient. The PharmD Clinic services are provided free to patients, and follow-up was determined on an individual basis by the clinical pharmacist. Funding for the services was provided under clinical appointment from the university. Patients also continued to see the primary care provider at intervals determined by the provider, typically every 4 to 6 months.
In total, 804 patients were screened for inclusion in the study. Inclusion criteria included 6 months of treatment from primary care provider prior to referral appointment with documented body mass index (BMI) and total body weight (TBW), attending at least one appointment for the disease-state management service in the PharmD Clinic, having a BMI of greater than 25 kg/m 2 , or diagnosis of diabetes and follow-up with either the PharmD Clinic or primary care provider for at least 6 months with documented BMI and TBW after the initial PharmD Clinic appointment. Of those screened, 366 patients met criteria. All data were analyzed using SYSTAT software. Repeated-measures ANOVA with Bonferroni correction was performed on all data as well as logistic regression.
Interventions
The clinical pharmacists utilized appropriate disease-state guidelines in addition to counseling techniques such as motivational interviewing to provide intervention including medication change recommendations to the primary care provider, nutrition and exercise counseling, behavior change counseling, and support for the patients seen. Pharmacists were able to make recommendations for weight loss medications, but required approval and prescribing 
Outcome
The primary outcome of this study was to determine if the pharmacist service intervention resulted in improved health outcomes at 6 months postintervention, defined as a statistically significant decrease in TBW, BMI, or HgbA1c compared to standard care 12 months prior to the intervention. Intervention time periods were defined as 6 months prior to the initial consult appointment with PharmD Clinic and 6 months after the initial consult appointment with the PharmD Clinic.
Results
Over the calendar year, 366 individual patients diagnosed with obesity seen in the PharmD Clinic met criteria for inclusion. The majority of patients were referred to the PharmD Clinic for management of type 2 diabetes, with over two thirds of the total patient population previously diagnosed with hypertension and dyslipidemia ( Table 2) .
During the initial PharmD consultation, the patients had a mean A1c of 7.9%, TBW of 99.7 kg, and BMI of 35.3 kg/ m 2 . Six months prior to consultation with the PharmD, the A1c, body weight, and BMI had all steadily increased. There was an average of 3.9 appointments with the PharmD Clinic. Overall, there was a significant improvement in TBW, BMI, and A1c during the time period of original consult to 6 months after consult with the PharmD (P < .001, Bonferroni correction applied for multiple comparisons). See Figures 1 and 2 . There was a nonsignificant worsening of TBW, BMI, and A1c the 6 months prior to PharmD Clinic intervention. The majority of interventions by the PharmD Clinic were lifestyle only, followed by lifestyle plus pharmacological agent(s) ( Table 3 ). The rate of acceptance of recommendations was not included in the data if only pharmacological agents were utilized. The binary logistic regression found none of the potential predictors of at least 5% weight loss to be statistically significant (Table 4) . This included the number of appointments and the type of intervention (pharmacological or nonpharmacological).
Discussion
Currently, obesity as a disease state is not being adequately addressed in the United States. Finding effective programs and health care providers to provide programs to assist in weight loss is essential to combating the epidemic. This retrospective study showed the value of having pharmacists involved in obesity management as evidenced by significant improvement in TBW, BMI, and A1c. The pharmacy service was able to not only make significant improvements in outcomes but also potentially alter the course of the disease states as both obesity and diabetes measurements were worsening under primary care treatment alone. This study's results indicate that patients' obesity markers were significantly improved after an intervention by a pharmacist. As pharmacists currently do not have a wellidentified role in obesity management, these results display the effectiveness of the intervention and show that in addition to primary care, the pharmacist intervention was beneficial. Mean A1c was also significantly improved, which provides further evidence that pharmacists have value in managing diabetes as part of the medical team, which is also a significant comorbidity of obesity. 9 The second conclusion from this study was that, although nonsignificant, markers for obesity and diabetes control were getting worse under primary care alone in the 6 months leading up to the intervention. This shows evidence that continuing to provide standard care alone for patients with diabetes and/or obesity is not adequate. The third conclusion from this study was that the majority of the weight loss occurred without the use of pharmacotherapy agents. Although often recommended by the pharmacist to the primary care provider, the decision to prescribe weight An aspect of this study that differentiates it from previous research is that no formal programming was established. Interventions were individualized to the patient. On one hand, the results could be more difficult to replicate in other clinical environments without a formal program; however, the study was completed by 2 pharmacists in 2 different clinics and found no significant difference in the results. Individualized treatment plans may be preferred for this patient population and clinical pharmacists are equipped to make these clinical decisions as supported by this data.
There are a few limitations of this study. First, it is retrospective in nature and all gathered information relied on appropriate documentation in the electronic medical record, meaning that missing information required the exclusion of a large number of patients. Second, no identifying factors based on logistic regression predicted success, which may limit the applicability of the results. Third, this study was performed in 2 clinics in one area of the country with a limited patient population. Fourth, each patient served as their own control, assuming no changes would be made without this study's intervention. Because of these limitations, the applicability of this study to other clinical scenarios may differ.
Conclusion
In conclusion, the results of this study showed significant improvement in markers of obesity and A1c after a pharmacist intervention when compared to primary care alone. Patient obesity outcomes continued to worsen under primary care treatment alone; however, they were statistically significantly improved with addition of a pharmacist as part of the health care team. These results indicate that pharmacists should be actively involved as part of the health care team in obesity and diabetes management.
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